سعر ريبلسس 14 مجم 30 قرص 2024

Oral semaglutide 14 mg tablets, 30 per pack (Novo Nordisk), a GLP-1 receptor agonist for adults with type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in adults with type 2 diabetes at high risk of these events.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (5% or more): nausea, abdominal pain, diarrhoea, decreased appetite, vomiting and constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity to semaglutide or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING: risk of thyroid C-cell tumours (seen in rodents; human relevance unknown). Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute pancreatitis: discontinue if suspected; do not restart if confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Diabetic retinopathy complications: monitor patients with a history of diabetic retinopathy.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Insulin secretagogues (e.g. sulfonylureas) or insulinIncreased risk of hypoglycaemia; consider reducing the dose of the secretagogue or insulin.DailyMed (U.S. National Library of Medicine)
• LevothyroxineLevothyroxine exposure increased by 33% when co-administered; consider monitoring thyroid parameters.DailyMed (U.S. National Library of Medicine)
• Other oral medicationsSemaglutide delays gastric emptying and may affect absorption of other oral drugs; follow the 30-minute administration instructions.DailyMed (U.S. National Library of Medicine)

• Human data are insufficient to evaluate drug-associated risk; animal studies suggest potential fetal risk. Discontinue at least 2 months before a planned pregnancy because of the long half-life.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended: semaglutide was below quantification in milk, but the absorption enhancer SNAC and/or its metabolites are present in human milk and may accumulate in infants.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.